- Home
- MDGL vs SF Comparison
MDGL vs SF Comparison
Compare MDGL & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDGL | SF |
|---|---|---|
| Founded | 2011 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.2B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDGL | SF |
|---|---|---|
| Price | $545.73 | $79.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $674.45 | $90.33 |
| AVG Volume (30 Days) | 307.9K | ★ 1.3M |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,133,000.00 | N/A |
| Revenue This Year | $58.39 | $14.58 |
| Revenue Next Year | $48.55 | $8.03 |
| P/E Ratio | ★ N/A | $20.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $286.75 | $67.81 |
| 52 Week High | $615.00 | $134.74 |
Technical Indicators
Market Signals| Indicator | MDGL | SF |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 63.08 |
| Support Level | $529.02 | $75.78 |
| Resistance Level | $545.29 | $79.12 |
| Average True Range (ATR) | 20.15 | 1.71 |
| MACD | -1.49 | 0.42 |
| Stochastic Oscillator | 30.54 | 88.76 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from trading and investment banking.